Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Inhibiting MDM2 to promote apoptosis in ALL

BGICC 2019

Published: 23 Jan 2019

Views: 1343

Rating:

Save

Prof Binghe Wang - Georgia State University, Atlanta, USA

Prof Binghe Wang speaks to ecancer at BGICC 2019 in Cairo about the regulation of p53 for acute lymphocytic leukaemia.

His study focussed on inhibiting the protein MDM2 which inhibits p53, thus encouraging apoptosis in cancer cells through the proteasome.

After outlining the mechanism in detail, he describes the next steps for the development of this research.

Related Videos

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Osimertinib plus chemotherapy shows superior results versus osimertinib alone...

Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer ( Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment

Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA

Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment ( Dr Nausheen Ahmed - The University of Kansas Cancer, Kansas, USA )

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

More from ecancer